gs1-08: "cctgma.32, a phase iii randomized double-blind placebo controlled adjuvant trial of..."
Published 1 year ago • 46 plays • Length 9:59Download video MP4
Download video MP3
Similar videos
-
9:41
gs1-02: "randomized, double-blind, phase 3 study of pembrolizumab chemotherapy vs placebo..."
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
9:15
gs1-06: "a randomized control phase iii trial of entinostat, a once weekly, class i selective..."
-
11:07
gs1-10: "clinical utility of molecular tumor profiling: results from the randomized trial..."
-
10:37
gs4-09. quality of life results from olympia:
-
8:11
san antonio breast cancer symposium 2008: big 1-98: letrozole vs tamoxifen
-
10:49
gs1-09: "inhibition of gpx4 induces preferential death of p53-mutant triple negative breast..."
-
23:28
sircentre asgn1 1
-
52:08
imaging the spatial distribution of metabolites, lipids, and cell types in human and mouse liver
-
1:41:26
education session: trends in adjuvant endocrine therapy
-
14:56
gs1 03 discussant hope s rugo
-
2:53
react: effect of celecoxib vs placebo as adjuvant therapy on dfs among patients with breast cancer
-
12:11
gs2-08: discussant
-
16:31
gs1-00: "single-cell spatial analysis by imaging mass cytometry and immunotherapy response in..."
-
5:25
san antonio breast cancer symposium 2008: zoledronic acid may have anti-tumour properties
-
16:51
dr. jan liefers gerrit | san antonio breast cancer symposium 2022 | general session
-
12:11
gs3-09: "loss of asxl1 tumor suppressor promotes resistance to cdk4/6 inhibitors in er breast..."
-
10:05
gs2-05: "randomized comparison of adjuvant aromatase inhibitor exemestane (e) plus ovarian..."
-
30:56
adjuvant treatment for early stage hormone positive breast cancer: role of genomic signatures
-
4:18
adjuvant et /- 1 year of everolimus in patients with high-risk hr-positive, her2-negative bc
-
1:27
dr. abou-alfa discusses the storm trial in hcc